ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Meeting Abstract

authors

Vinik, Aaron I.

publication date

January 1, 2014

webpage

Web of Science

published in

NEUROENDOCRINOLOGY Journal

start page

271

end page

271

volume

99

issue

3-4